BioTech Funding Portal
BioTech Funding Portal (biotech.fund) is a Regulation Crowdfunding portal only for life-science companies, open to accredited and non-accredited investors with minimums from $500. It filed its funding portal registration in November 2024 and announced its public launch on June 22, 2026; as of November 9, 2026 no company has filed an offering through it. Its offerings page lists two drug developers Testing the Waters, each proposing a $1 million raise on a SAFE: Glafabra Therapeutics (Fabry disease; $12 million cap, 20% discount, $1,000 minimum) and Energesis Pharmaceuticals (obesity; CrowdSAFE, $500 minimum). The terms are preliminary and the listings accept only expressions of interest. A fictional demo company sits beside them. Investors pay no portal fee; issuers' fees will appear in each Form C.

No platform response on record for this profile. Is this your platform? Respond or claim it.
Platform Identity
- Website
- biotech.fund
- Headquarters
- Chicago, IL, US
- Founded
- 2024
- Parent
- BioTech Funding Portal LLC (Delaware, formed July 22, 2024; first registered as BioTech Social Crowdfunding Portal LLC), 222 W Merchandise Mart Plaza #228, Chicago, IL; wholly owned by BioTech Social, Inc. (Delaware corporation, 11140 Rockville Pike, Rockville, MD). Co-founders Dr. Neva West (CEO) and Brian Christie (chair; CEO of Brainsy, Inc.; 2024 President of the Crowdfunding Professional Association).
- Platform type
- Regulation Crowdfunding Portal (Life Sciences)
- Regulatory
- finra_member
- Eligibility
- retail
AltStreet Coverage
- Review status
- Published
- Coverage type
- Investment platform
- Review date
- Nov 9, 2026
- Last updated
- Nov 10, 2026
- Composite score
- 2.5
Key Data Points
- EDGAR-linked offerings
- 2
Reference Reading
AltStreet reference pages on the filings and mechanics behind this platform's category.
Claim a Verified Profile.
Verified Profiles give covered platforms a structured channel to respond to AltStreet's editorial framework with source-documented amendments, additional disclosures, and attributed corrections — improving signal quality for buyers and investors evaluating your platform.
